Papilio.Bio
Enables rapid self-administered HPV screening with digital app integration for easy diagnostics, empowering accessible sexual health management.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Support Program | |
| Total Funding | 000k | ||
Related Content
Papilio.bio is a health technology startup dedicated to improving cervical cancer prevention by transforming the way Human Papillomavirus (HPV) screening is delivered. Recognizing the global health burden of cervical cancer—one of the most preventable yet deadly cancers for women—Papilio.bio aims to close the gaps in current screening programs by offering a more accessible, user-friendly, and effective solution.
The company develops innovative tools that enable self-sampling and more personalized screening, lowering the barriers for women who may face logistical, cultural, or psychological obstacles to conventional gynecological testing. Their approach is rooted in the belief that healthcare systems can reach more patients by empowering them to take control of their own health, while still delivering clinically validated, reliable results.
Papilio.bio’s technology is designed to support national screening programs as well as private healthcare providers by increasing screening uptake, reducing missed cases, and ultimately helping to achieve the World Health Organization’s target of eliminating cervical cancer as a public health problem. Their product pipeline is informed by strong microbiological expertise and a commitment to evidence-based design, ensuring that the solutions are both scientifically robust and practical for large-scale implementation.
The company’s multidisciplinary team includes specialists in microbiology, biomedical engineering, clinical research, and healthcare innovation. They work in collaboration with leading scientific advisors and experts in HPV vaccine development to ensure the highest standards of safety and efficacy. Papilio.bio also engages in partnerships with healthcare systems and stakeholders to pilot and deploy their solutions, demonstrating a commitment to real-world impact.
By simplifying the screening process and making it more accessible, Papilio.bio aims to overcome long-standing barriers to cervical cancer prevention, reduce inequalities in women’s health, and support global efforts to save lives through early detection and treatment.
Keywords: health technology, cervical cancer, HPV screening, self-sampling, women's health, prevention, microbiology, healthcare innovation, early detection, public health